Welcome to MD3D: Positioning of new S1P receptor modulators to optimize patient outcomes in ulcerative colitis (UC). This four-part learning series includes expert perspectives, case studies, and 3D animations that cover key practice points, an inside view of disease pathways and treatment mechanisms, and the application of clinical UC management strategies. The animation and accompanying written documentation provide patients and their caregivers with easy-to-understand resources.
Learning objectives:
After completing all four episodes in this series, learners should possess:
- Knowledge of the mechanisms of action, available clinical data, and risk-benefit profiles for new S1P receptor-modulating therapies.
- Competence positioning these new therapies in the context of current unmet medical needs for moderate to severe UC.
- Knowledge of UC guideline recommendations, including treat-to-target approaches for therapeutic decision making.
- Competence in individualizing treatment for patients with UC, based on patient-, disease-, and treatment-related factors.
- Competence in applying shared decision making, including patient education and engagement strategies to improve treatment adherence.
- Knowledge of the disease burden of isolated proctitis (IP).
- Competence in utilizing available and emerging therapeutic approaches to improve quality of life and symptom burden for patients with IP.
Contributing Editor:
Michele Rubin, MSN, APRN, CNS-BC, CGRN
IBD Clinical Nurse Specialist
Department of Colorectal Surgery
University of Chicago
Chicago, Illinois
Sponsorship:
This series is supported by educational grants from Pfizer and Projects in Knowledge.
Release date: July 15, 2024
Termination Date: July 14, 2025
Midwest
If you missed our Midwest workshop, join us in-person or virtually at one of our remaining locations.
University of Chicago
Gleacher Center
Feb. 24, 2024
Course directors:
Northeast
If you missed our Northeast workshop, join us in-person or virtually at one of our remaining locations.
University of Pennsylvania
Jordan Medical Education Center - Law Auditorium
Jan. 20, 2024
Course directors:
Joint Accreditation Statement
CME expiration date: July 14, 2025
In support of improving patient care, Projects In Knowledge® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
Physicians
Projects In Knowledge® designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The CME credits that physicians earn from this activity will be submitted to ACCME’s CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.
Physician Assistants
Projects In Knowledge® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 Credit(s)™. Approval is valid until 07/14/2025. PAs should only claim credit commensurate with the extent of their participation.
Nurses
Upon completion of this course, participants will be awarded 0.5 nursing contact hour(s).
Joint Accreditation Nursing Provider Number: 4008235
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, or PIK endorsement of any commercial product or service.
Pharmacists
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This chapter is worth up to 0.5 contact hour(s)(0.05 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is JA4008235-0000-24-158-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
Disclosures
Projects In Knowledge® adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests)*. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Michele Rubin, MSN, APRN, CNS-BC, CGRN, has no relevant financial relationships to disclose.
Lisa Cimakasky, PhD (medical writer), has no relevant financial relationships to disclose.
Peer Reviewer has no relevant financial relationships to disclose.
Vandana G. Abramson, MD (IPE Committee) has no relevant financial relationships to disclose.
Jason D. Astrin, DMSc, MBA, PA-C, DFAAPA (IPE Committee) has no relevant financial relationships to disclose.
Ella Balasa, Patient Advocate (IPE Committee), has been a content creator for Health Union; and has been on the patient advisory board for Genentech, A Member of the Roche Group, Health Union, Medidata, Parexel, and ZS Consulting.
James D. Bowen, MD (IPE Committee), has received honoraria from Biogen, EMD Serono, Inc., Genentech, and Novartis; has received consulting fees from Biogen, Celgene, EMD Serono, Genentech, a Member of the Roche Group, and Novartis Pharmaceuticals Corporation; has conducted contracted research for Alexion Pharmaceuticals, Inc, Alkermes, Biogen, Celgene Corporation, Genentech, a Member of the Roche Group, Genzyme, Novartis Pharmaceuticals Corporation, and TG Therapeutics, Inc; and has ownership interest in Amgen Inc.
Anita Roy Desai, MD, FAAP (IPE Committee), has no relevant financial relationships to disclose.
Veronica Esquible, PharmD (IPE Committee), has no relevant financial relationships to disclose.
Bradley Monk, MD, FACOG, FACS (IPE Committee), has received consulting fees from AbbVie, Inc, Advaxis, Inc., Agenus Inc., Amgen Inc., Aravive, Inc., Asymmetric Therapeutics, Boston Biomedical, Chemocare, ChemoID, Circulogene, Conjupro Biotherapeutics Inc, Eisai Co., Ltd, Geistlich Pharma North America, Inc., Genmab/Seattle Genetics, GOG Foundation, Immunomedics, Inc., ImmunoGen, Inc., Incyte Corporation, Laekna Healthcare Private Limited, Mateon Therapeutics, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Mersana Therapeutics, Inc., Myriad Genetics, Nucana, OncoMed Pharmaceuticals, OncoQuest Inc., OncoSec Medical Inc, Perthera Inc., Pfizer Inc., Precision Oncology, Puma Biotechnology Inc, Regeneron Pharmaceuticals, Samumed, LLC, Takeda Pharmaceutical Company, Ltd, VBL Therapeutics, and Vigeo Therapeutics; and has been a Speaker/Consultant for AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche Ltd/ Genentech, A Member of the Roche Group, Janssen Pharmaceuticals/Johnson & Johnson, Inc., and Tesaro, Inc/GlaxoSmithKline.
Brant Oliver, PhD, MS, MPH, APRN-BC (IPE Committee), has conducted contracted research for Biogen and EMD Serono.
Ilon S. Rincon Portas, MD (IPE Committee), has no relevant financial relationships to disclose.
Katherine Sibler, MSN, WHNP-BC (IPE Committee), has no relevant financial relationships to disclose.
Projects In Knowledge staff members have no relevant financial relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
*An ineligible company (commercial interest) is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used, on patients.
Off-Label Drug Statement: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
